Neonatal encephalopathy (NE) results from impaired cerebral blood flow and oxygen delivery to the brain. The pathophysiology of NE is complex and our understanding of its underlying pathways continues to evolve. There is considerable evidence that cholesterol dysregulation is involved in several adult diseases, including traumatic brain injury, stroke, Huntington’s disease, and Parkinson’s disease. Although the research is less robust in pediatrics, there is emerging evidence that aberrations in cholesterol metabolism may also be involved in the pathophysiology of neonatal NE. This narrative review provides an overview of cholesterol metabolism in the brain along with several examples from the adult literature where pathologic alterations in cholesterol metabolism have been associated with inflammatory and ischemic brain injury. Using those data as a background, the review then discusses the current preclinical data supporting the involvement of cholesterol in the pathogenesis of NE as well as how brain-specific cholesterol metabolites may serve as serum biomarkers for brain injury. Lastly, we review the potential for using the cholesterol metabolic pathways as therapeutic targets. Further investigation of the shifts in cholesterol synthesis and metabolism after hypoxia–ischemia may prove vital in understanding NE pathophysiology as well as providing opportunities for rapid diagnosis and therapeutic interventions.
This review summarizes emerging evidence that aberrations in cholesterol metabolism may be involved in the pathophysiology of NE.
Using data from NE as well as analogous adult disease states, this article reviews the potential for using cholesterol pathways as targets for developing novel therapeutic interventions and using cholesterol metabolites as biomarkers for injury.
When possible, gaps in the current literature were identified to aid in the development of future studies to further investigate the interactions between cholesterol pathways and NE.
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kurinczuk, J. J., White-Koning, M. & Badawi, N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum. Dev. 86, 329–338 (2010).
Allen, K. A. & Brandon, D. H. Hypoxic ischemic encephalopathy: pathophysiology and experimental treatments. Newborn Infant Nurs. Rev. 11, 125–133 (2011).
Douglas-Escobar, M. & Weiss, M. D. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA Pediatr. 169, 397–403 (2015).
Yu, Z. et al. Hypoxia-ischemia brain damage disrupts brain cholesterol homeostasis in neonatal rats. Neuropediatrics 40, 179–185 (2009).
Bruns, N. et al. Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to neonates. J. Vis. Exp. 127, (2017).
Chandrasekaran, M., Chaban, B., Montaldo, P. & Thayyil, S. Predictive value of amplitude-integrated EEG (aEEG) after rescue hypothermic neuroprotection for hypoxic ischemic encephalopathy: a meta-analysis. J. Perinatol. 37, 684–689 (2017).
Del Río, R. et al. Amplitude integrated electroencephalogram as a prognostic tool in neonates with hypoxic-ischemic encephalopathy: a systematic review. PLoS ONE 11, e0165744 (2016).
Hackam, D. G. & Hegele, R. A. Cholesterol lowering and prevention of stroke. Stroke 50, 537–541 (2019).
Kay, A. D. et al. Remodeling of cerebrospinal fluid lipoprotein particles after human traumatic brain injury. J. Neurotrauma 20, 717–723 (2003).
Björkhem, I. & Hansson, M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396, 46–49 (2010).
Fitzky, B. U. et al. Mutations in the Delta7-sterol reductase gene in patients with the Smith–Lemli–Opitz syndrome. Proc. Natl Acad. Sci. USA 95, 8181–8186 (1998).
Lu, F. et al. Upregulation of cholesterol 24-hydroxylase following hypoxia-ischemia in neonatal mouse brain. Pediatr. Res. 83, 1218–1227 (2018).
Ramirez, M. R. et al. Neonatal hypoxia-ischemia reduces ganglioside, phospholipid and cholesterol contents in the rat hippocampus. Neurosci. Res. 46, 339–347 (2003).
Zhang, J. & Liu, Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 6, 254–264 (2015).
Alphonse, P. A. S. & Jones, P. J. H. Revisiting human cholesterol synthesis and absorption: the reciprocity paradigm and its key regulators. Lipids 51, 519–536 (2016).
Dietschy, J. M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 390, 287–293 (2009).
Sun, M.-Y. et al. 24(S)-Hydroxycholesterol as a modulator of neuronal signaling and survival. Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry 22, 132–144 (2016).
Genaro-Mattos, T. C. et al. Cholesterol biosynthesis and uptake in developing neurons. ACS Chem. Neurosci. 10, 3671–3681 (2019).
Zerenturk, E. J., Sharpe, L. J., Ikonen, E. & Brown, A. J. Desmosterol and DHCR24: unexpected new directions for a terminal step in cholesterol synthesis. Prog. Lipid Res. 52, 666–680 (2013).
Jansen, M. et al. What dictates the accumulation of desmosterol in the developing brain? FASEB J. 27, 865–870 (2013).
Hernández-Jiménez, M. et al. Seladin-1/DHCR24 is neuroprotective by associating EAAT2 glutamate transporter to lipid rafts in experimental stroke. Stroke 47, 206–213 (2016).
Nguyen, A. D., McDonald, J. G., Bruick, R. K. & DeBose-Boyd, R. A. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J. Biol. Chem. 282, 27436–27446 (2007).
Dorszewska, J. & Adamczewska-Goncerzewicz, Z. Patterns of free and esterified sterol fractions of the cerebral white matter in severe and moderate experimental hypoxia. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 6, 227–231 (2000).
Wender, M., Adamczewska-Goncerzewicz, Z., Doroszewska, J. & Szczech, J. Free sterols in the rat white matter following experimental global ischemia. Exp. Toxicol. Pathol. 49, 57–59 (1997).
Cartagena, C. M. et al. Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain. J. Neurotrauma 25, 1087–1098 (2008).
Cartagena, C. M., Burns, M. P. & Rebeck, G. W. 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. Brain Res. 1319, 1–12 (2010).
Lu, F. et al. Serum 24S-hydroxycholesterol predicts long-term brain structural and functional outcomes after hypoxia-ischemia in neonatal mice. J. Cereb. Blood Flow Metab. 271678X20911910 (2020).
Björkhem, I. et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39, 1594–1600 (1998).
Emnett, C. M. et al. Interaction between positive allosteric modulators and trapping blockers of the NMDA receptor channel. Br. J. Pharm. 172, 1333–1347 (2015).
Grayaa, S. et al. Plasma oxysterol profiling in children reveals 24-hydroxycholesterol as a potential marker for Autism Spectrum Disorders. Biochimie 153, 80–85 (2018).
Björkhem, I. et al. Oxysterols and Parkinson’s disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci. Lett. 555, 102–105 (2013).
Leoni, V. et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci. Lett. 331, 163–166 (2002).
Ye, J. & DeBose-Boyd, R. A. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb. Perspect. Biol. 3, 7. https://cshperspectives.cshlp.org/content/3/7/a004754.long (2011).
Eberlé, D. et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86, 839–848 (2004).
Vergnes, L. et al. SREBP-2-deficient and hypomorphic mice reveal roles for SREBP-2 in embryonic development and SREBP-1c expression. J. Lipid Rs. 57, 410–421 (2016).
Ferris, H. A. et al. Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. Proc. Natl Acad. Sci. USA 114, 1189–1194 (2017).
Woollett, L. A. Review: Transport of maternal cholesterol to the fetal circulation. Placenta 32, S218–S221 (2011).
Woollett, L. A. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am. J. Clin. Nutr. 82, 1155–1161 (2005).
McConihay, J. A., Horn, P. S. & Woollett, L. A. Effect of maternal hypercholesterolemia on fetal sterol metabolism in the Golden Syrian hamster. J. Lipid Res. 42, 1111–1119 (2001).
Tint, G. S. et al. The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterols. J. Lipid Res. 47, 1535–1541 (2006).
Tint, G. S. et al. Desmosterol in brain is elevated because DHCR24 needs REST for robust expression but REST is poorly expressed. Dev. Neurosci. 36, 132–142 (2014).
Jurevics, H. A., Kidwai, F. Z. & Morell, P. Sources of cholesterol during development of the rat fetus and fetal organs. J. Lipid Res. 38, 723–733 (1997).
Pfrieger, F. W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 50, 357–371 (2011).
Nägler, K., Mauch, D. H. & Pfrieger, F. W. Glia-derived signals induce synapse formation in neurones of the rat central nervous system. J. Physiol. 533, 665–679 (2001).
Ullian, E. M., Sapperstein, S. K., Christopherson, K. S. & Barres, B. A. Control of synapse number by glia. Science 291, 657–661 (2001).
Hinse, C. H. & Shah, S. N. The desmosterol reductase activity of rat brain during development. J. Neurochem. 18, 1989–1998 (1971).
Nie, S., Chen, G., Cao, X. & Zhang, Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J. Rare Dis. 9, 179 (2014).
Ben Hamida, M. et al. Peripheral neuropathy in a sporadic case of cerebrotendinous xanthomatosis. Rev. Neurol. 147, 385–388 (1991).
Tint, G. S. et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N. Engl. J. Med. 330, 107–113 (1994).
Tint, G. S. et al. Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome. J. Pediatr. 127, 82–87 (1995).
Nowaczyk, M. J. M. & Irons, M. B. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. Am. J. Med. Genet. C 160C, 250–262 (2012).
Tierney, E., Conley, S. K., Goodwin, H. & Porter, F. D. Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. A 152A, 91–95 (2010).
Porter, F. D. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 16, 535–541 (2008).
Fitzky, B. U. et al. 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J. Clin. Invest. 108, 905–915 (2001).
Sodero, A. O. et al. Cholesterol loss during glutamate-mediated excitotoxicity. EMBO J. 31, 1764–1773 (2012).
Catapano, A. L., Pirillo, A. & Norata, G. D. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br. J. Pharm. 174, 3973–3985 (2017).
Martiskainen, H. et al. DHCR24 exerts neuroprotection upon inflammation-induced neuronal death. J. Neuroinflamm. 14, 215 (2017).
Yatsu, F. M. & Moss, S. A. Brain lipid changes following hypoxia. Stroke 2, 587–593 (1971).
Kacher, R. et al. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington’s disease. Brain J. Neurol. 142, 2432–2450 (2019).
del Toro, D. et al. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington’s disease. J. Neurochem. 115, 153–167 (2010).
Valenza, M. et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J. Neurosci. J. Soc. Neurosci. 25, 9932–9939 (2005).
Hu, G. et al. Total cholesterol and the risk of Parkinson disease. Neurology 70, 1972–1979 (2008).
Hu, G. et al. Body mass index and the risk of Parkinson disease. Neurology 67, 1955–1959 (2006).
Doria, M. et al. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson’s disease. Free Radic. Biol. Med. 101, 393–400 (2016).
Lee, C.-Y. J. et al. Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson’s disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid. Redox Signal. 11, 407–420 (2009).
Choi, J.-Y., Jang, E.-H., Park, C.-S. & Kang, J.-H. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 38, 806–816 (2005).
Bousquet, M. et al. High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol. Dis. 45, 529–538 (2012).
Lim, L. et al. Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson’s disease. Cell Death Differ. 19, 416–427 (2012).
Xiong, Y., Zhang, Y., Mahmood, A. & Chopp, M. Investigational agents for treatment of traumatic brain injury. Expert Opin. Investig. Drugs 24, 743–760 (2015).
Morganti-Kossmann, M. C., Satgunaseelan, L., Bye, N. & Kossmann, T. Modulation of immune response by head injury. Injury 38, 1392–1400 (2007).
Wang, J. et al. Traumatic brain injury leads to accelerated atherosclerosis in apolipoprotein E deficient mice. Sci. Rep. 8, 5639 (2018).
Weiner, M. F. et al. Plasma 24S-hydroxycholesterol and other oxysterols in acute closed head injury. Brain Inj. 22, 611–615 (2008).
Saher, G. & Stumpf, S. K. Cholesterol in myelin biogenesis and hypomyelinating disorders. Biochim. Biophys. Acta 1851, 1083–1094 (2015).
Linsenbardt, A. J. et al. Different oxysterols have opposing actions at N-methyl-D-aspartate receptors. Neuropharmacology 85, 232–242 (2014).
Jun, J. C. et al. Thermoneutrality modifies the impact of hypoxia on lipid metabolism. Am. J. Physiol. 304, E424–E435 (2013).
Denihan, N. M., Boylan, G. B. & Murray, D. M. Metabolomic profiling in perinatal asphyxia: a promising new field. BioMed. Res. Int. 2015, 254076 (2015).
Fabelo, N. et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol. Med. 17, 1107–1118 (2011).
Schönknecht, P. et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer’s disease compared to healthy controls. Neurosci. Lett. 324, 83–85 (2002).
Papassotiropoulos, A. et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease. NeuroReport 11, 1959–1962 (2000).
Sato, Y. et al. Identification of a new plasma biomarker of Alzheimer’s disease using metabolomics technology. J. Lipid Res. 53, 567–576 (2012).
Wakamatsu, H. et al. Serum desmosterol and other lipids in myotonic dystrophy-a possible pathogenesis of myotonic dystrophy. Keio J. Med. 19, 145–149 (1970).
Berghoff, S. A. et al. Dietary cholesterol promotes repair of demyelinated lesions in the adult brain. Nat. Commun. 8, 14241 (2017).
Chong, A. J. et al. The neuroprotective effects of simvastatin on high cholesterol following traumatic brain injury in rats. World Neurosurg. 132, e99–e108 (2019).
Sikora, D. M. et al. Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J. Pediatr. 144, 783–791 (2004).
Ridker, P. M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959–1965 (2001).
Wible, E. F. & Laskowitz, D. T. Statins in traumatic brain injury. Neurother. J. Am. Soc. Exp. Neurother. 7, 62–73 (2010).
Xu, X. et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J. Neuroinflamm. 14, 167 (2017).
He, X. et al. Lovastatin modulates increased cholesterol and oxysterol levels and has a neuroprotective effect on rat hippocampal neurons after kainate injury. J. Neuropathol. Exp. Neurol. 65, 652–663 (2006).
Wassif, C. A. et al. A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome. Genet. Med. 19, 297–305 (2017).
Jira, P. E. et al. Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. J. Lipid Res. 41, 1339–1346 (2000).
Verrips, A. et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 48, 233–238 (1999).
Balduini, W., De Angelis, V., Mazzoni, E. & Cimino, M. Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke 32, 2185–2191 (2001).
Carloni, S. & Balduini, W. Simvastatin preconditioning confers neuroprotection against hypoxia-ischemia induced brain damage in neonatal rats via autophagy and silent information regulator 1 (SIRT1) activation. Exp. Neurol. 324, 113117 (2020).
Li, A. et al. Simvastatin attenuates hypomyelination induced by hypoxia-ischemia in neonatal rats. Neurol. Res. 32, 945–952 (2010).
Rufini, S. et al. Cholesterol depletion inhibits electrophysiological changes induced by anoxia in CA1 region of rat hippocampal slices. Brain Res. 1298, 178–185 (2009).
Balduini, W. et al. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 34, 2007–2012 (2003).
We thank Dr. Zeljka Korade for her support and advice during the process of writing this review.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Dave, A.M., Peeples, E.S. Cholesterol metabolism and brain injury in neonatal encephalopathy. Pediatr Res 90, 37–44 (2021). https://doi.org/10.1038/s41390-020-01218-3